Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection.

Autor: Tyack L; Queensland Paediatric Rehabilitation Service, Queensland Children's Hospital, Brisbane, Queensland, Australia., Copeland L; Queensland Paediatric Rehabilitation Service, Queensland Children's Hospital, Brisbane, Queensland, Australia., McCartney L; Kids Rehab, The Sydney Children's Hospitals Network Randwick and Westmead, Sydney, New South Wales, Australia., Waugh MC; Kids Rehab, The Sydney Children's Hospitals Network Randwick and Westmead, Sydney, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Journal of paediatrics and child health [J Paediatr Child Health] 2021 Feb; Vol. 57 (2), pp. 258-262. Date of Electronic Publication: 2020 Sep 25.
DOI: 10.1111/jpc.15194
Abstrakt: Aim: This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs.
Methods: AE data were extracted from the Australian Paediatric ITB Research Group national database, to include the first 5 years of data collection. Raw data were collated and analysed descriptively.
Results: Data were collected for 40 patients. Forty-seven AEs in 23 patients were reported. Ten (25%) patients required surgical intervention related to their AE. Five patients (12.5%) required pump removal. The most frequent ITB-related AEs were catheter dysfunction (24%), drug overdose, withdrawal or sensitivity (19%), seromas and haematomas (15%) and infections (13%).
Conclusions: The AE rate for ITB therapy is high and needs to be considered when counselling patients regarding ITB as a therapeutic option.
(© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).)
Databáze: MEDLINE
Externí odkaz: